Publications by authors named "Cathinka H Julin"

Article Synopsis
  • Barriers to Trials
  • : The Centre for Epidemic Interventions Research in Norway faced many challenges while trying to conduct randomized trials during the COVID-19 pandemic, leading to the failure of 11 out of 18 proposed trials.
  • Legal and Ethical Issues
  • : A significant obstacle came from the Norwegian Health Research Act, which requires informed consent from all trial participants, complicating the implementation of these studies.
  • Need for Support and Framework
  • : The authors concluded that for future pandemic research, it's essential to have both political backing and a legal structure that facilitates conducting such trials effectively.
View Article and Find Full Text PDF

Importance: Understanding the susceptibility and infectiousness of children and adolescents in comparison to adults is important to appreciate their role in the COVID-19 pandemic.

Objective: To determine SARS-CoV-2 susceptibility and infectiousness of children and adolescents with adults as comparator for three variants (wild-type, alpha, delta) in the household setting. We aimed to identify the effects independent of vaccination or prior infection.

View Article and Find Full Text PDF

Background: Vaccination constitutes an attractive control measure for hepatitis E virus (HEV), a major cause of maternal and perinatal mortality globally. Analysis of pregnant participants in an effectiveness trial of the HEV vaccine HEV239 showed possible HEV239-associated fetal losses. We aimed to conduct a detailed analysis of this safety signal.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted in Bangladesh to evaluate the safety and effectiveness of a recombinant hepatitis E vaccine (HEV239) in preventing hepatitis E during pregnancy, focusing on pregnant and non-pregnant women aged 16-39.
  • The trial involved 67 villages and included over 19,000 participants who received either HEV239 or a control hepatitis B vaccine (Hepa-B), with follow-up for two years post-vaccination.
  • Results showed no cases of hepatitis E among pregnant participants in either group, indicating HEV239's mild safety profile was comparable to Hepa-B, with no significant adverse events reported.
View Article and Find Full Text PDF

HEV is the most common cause of acute hepatitis globally. This review summarizes the latest knowledge on the epidemiology, clinical characteristics, testing, and treatment of HEV infection. We also focused on Bangladesh to highlight the distinct challenges and the possible remedies.

View Article and Find Full Text PDF

Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide. In many low-income countries it causes large outbreaks and disproportionally affects pregnant women and their offspring. Surveillance studies to find effective preventive interventions are needed but are hampered by the lack of funding and infrastructure.

View Article and Find Full Text PDF

We studied the secondary attack rate (SAR), risk factors, and precautionary practices of household transmission in a prospective, longitudinal study. We further compared transmission between the Alpha (B.1.

View Article and Find Full Text PDF

Introduction: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis in the developing world and is a public health problem, in particular among pregnant women, where it may lead to severe or fatal complications. A recombinant HEV vaccine, 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China), is licensed in China, but WHO calls for further studies to evaluate the safety and immunogenicity of this vaccine in vulnerable populations, and to evaluate protection in pregnancy. We are therefore conducting a phase IV trial to assess the effectiveness, safety and immunogenicity of the HEV 239 vaccine when given in women of childbearing age in rural Bangladesh, where HEV infection is endemic.

View Article and Find Full Text PDF

Background: Histone deacetylase inhibitors (HDACis) like vorinostat are promising radiosensitisers in prostate cancer, but their effect under hypoxia is not known. We investigated gene expression associated with radiosensitisation of normoxic and hypoxic prostate cancer cells by vorinostat.

Methods: Cells were exposed to vorinostat under normoxia or hypoxia and subjected to gene expression profiling before irradiation and clonogenic survival analysis.

View Article and Find Full Text PDF

Purpose: A 31-gene expression signature reflected in dynamic contrast enhanced (DCE)-MR images and correlated with hypoxia-related aggressiveness in cervical cancer was identified in previous work. We here aimed to construct a dichotomous classifier with key signature genes and a predefined classification threshold that separated cervical cancer patients into a more and less hypoxic group with different outcome to chemoradiotherapy.

Experimental Design: A training cohort of 42 patients and two independent cohorts of 108 and 131 patients were included.

View Article and Find Full Text PDF